Keeps Biopharma Inc. (KOSDAQ:256940)

Keeps Biopharma Statistics

Total Valuation

Keeps Biopharma has a market cap or net worth of KRW 205.60 billion. The enterprise value is 244.45 billion.

Market Cap	205.60B
Enterprise Value	244.45B

Important Dates

The next estimated earnings date is Tuesday, November 11, 2025.

Earnings Date	Nov 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Keeps Biopharma has 20.08 million shares outstanding. The number of shares has increased by 0.31% in one year.

Current Share Class	20.08M
Shares Outstanding	20.08M
Shares Change (YoY)	+0.31%
Shares Change (QoQ)	+2.97%
Owned by Insiders (%)	4.13%
Owned by Institutions (%)	4.21%
Float	14.74M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.39
PB Ratio	2.31
P/TBV Ratio	7.59
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-196.94
EV / Sales	1.65
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-19.01

Financial Position

The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.78.

Current Ratio	1.53
Quick Ratio	0.87
Debt / Equity	0.78
Debt / EBITDA	38.46
Debt / FCF	-5.40
Interest Coverage	-0.21

Financial Efficiency

Return on equity (ROE) is -0.98% and return on invested capital (ROIC) is -0.56%.

Return on Equity (ROE)	-0.98%
Return on Assets (ROA)	-0.42%
Return on Invested Capital (ROIC)	-0.56%
Return on Capital Employed (ROCE)	-0.85%
Revenue Per Employee	5.30B
Profits Per Employee	-44.33M
Employee Count	28
Asset Turnover	0.85
Inventory Turnover	9.19

Taxes

Income Tax	-2.86B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +81.03% in the last 52 weeks. The beta is 1.64, so Keeps Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.64
52-Week Price Change	+81.03%
50-Day Moving Average	12,039.80
200-Day Moving Average	11,345.33
Relative Strength Index (RSI)	40.65
Average Volume (20 Days)	92,694

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Keeps Biopharma had revenue of KRW 148.36 billion and -1.24 billion in losses. Loss per share was -65.51.

Revenue	148.36B
Gross Profit	23.43B
Operating Income	-1.18B
Pretax Income	-3.60B
Net Income	-1.24B
EBITDA	1.80B
EBIT	-1.18B
Loss Per Share	-65.51

Balance Sheet

The company has 44.87 billion in cash and 69.38 billion in debt, giving a net cash position of -24.52 billion or -1,221.08 per share.

Cash & Cash Equivalents	44.87B
Total Debt	69.38B
Net Cash	-24.52B
Net Cash Per Share	-1,221.08
Equity (Book Value)	88.82B
Book Value Per Share	3,709.85
Working Capital	38.04B

Cash Flow

In the last 12 months, operating cash flow was -4.51 billion and capital expenditures -8.35 billion, giving a free cash flow of -12.86 billion.

Operating Cash Flow	-4.51B
Capital Expenditures	-8.35B
Free Cash Flow	-12.86B
FCF Per Share	-640.34

Margins

Gross margin is 15.79%, with operating and profit margins of -0.79% and -0.84%.

Gross Margin	15.79%
Operating Margin	-0.79%
Pretax Margin	-2.43%
Profit Margin	-0.84%
EBITDA Margin	1.22%
EBIT Margin	-0.79%
FCF Margin	n/a

Dividends & Yields

Keeps Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.31%
Shareholder Yield	n/a
Earnings Yield	-0.60%
FCF Yield	-6.25%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 20, 2020. It was a forward split with a ratio of 3.

Last Split Date	May 20, 2020
Split Type	Forward
Split Ratio	3

Scores

Keeps Biopharma has an Altman Z-Score of 1.71 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.71
Piotroski F-Score	1